QINLOCK 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
IAIN/0015/G 
This was an application for a group of variations. 
17/08/2023 
n/a 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
A.5.b - Administrative change - Change in the name 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
IB/0012 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
21/06/2023 
SmPC 
life of the finished product - As packaged for sale 
(supported by real time data) 
PSUSA/10962
Periodic Safety Update EU Single assessment - 
08/06/2023 
n/a 
PRAC Recommendation - maintenance 
/202211 
ripretinib 
IB/0011 
C.I.11.z - Introduction of, or change(s) to, the 
11/05/2023 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
PSUSA/10962
Periodic Safety Update EU Single assessment - 
15/12/2022 
24/02/2023 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
/202205 
ripretinib 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/10962/202205. 
IB/0009 
B.I.a.1.z - Change in the manufacturer of AS or of a 
31/01/2023 
n/a 
starting material/reagent/intermediate for AS - Other 
variation 
II/0004 
Update of sections 4.2 and 5.2 of the SmPC in order 
26/01/2023 
SmPC and PL 
SmPC new text 
to change posology recommendations in patients 
with hepatic impairment and update the description 
of pharmacokinetics based on final results from 
Study DCC-2618-01-004; a Phase 1 study of the 
Page 2/4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pharmacokinetics, Safety, and Tolerability of 
Ripretinib in Subjects With Hepatic Impairment 
Compared to Healthy Control Subjects. The Package 
Leaflet is updated accordingly. The RMP version 2.2 
has also been submitted. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
IB/0008 
B.II.d.2.d - Change in test procedure for the finished 
08/11/2022 
n/a 
product - Other changes to a test procedure 
(including replacement or addition) 
IA/0007/G 
This was an application for a group of variations. 
27/10/2022 
n/a 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
IB/0005 
C.I.z - Changes (Safety/Efficacy) of Human and 
18/08/2022 
n/a 
Veterinary Medicinal Products - Other variation 
IB/0003 
B.I.a.1.z - Change in the manufacturer of AS or of a 
17/05/2022 
n/a 
starting material/reagent/intermediate for AS - Other 
variation 
II/0002 
C.I.13 - Other variations not specifically covered 
10/03/2022 
n/a 
Page 3/4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
elsewhere in this Annex which involve the submission 
of studies to the competent authority 
IAIN/0001/G 
This was an application for a group of variations. 
13/12/2021 
02/12/2022 
SmPC, Annex 
II, Labelling 
and PL 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
Page 4/4 
 
 
 
 
 
 
 
 
 
 
